- European Biotech company (Rare disease target)
- Supported with 2 FTEs for 12 months
- Elaboration of existing hits to elucidate SAR
- Rational design to deliver drug-like compounds
- Compounds screened by client (SPR and cell assays)
- >200 compounds prepared over four series
- Highly potent compounds with good ADME properties, clear SAR and in vivo efficacy
We are flexible in our approach – some clients wish to keep screening in-house, others ask that we manage and drive this process. Our goal is to provide a tailored service to suit clients’ aspirations and budget, but with a focus on excellence of delivery at all stages.
